Related Experiment Video

Updated: Jul 4, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Clinical observation of renal artery stenosis treated with PCSK9 inhibitor

Fali Zhao1, Qianping Gao2, Bo Jiang2

  • 1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, No.23, Post Street, Nangang District, Harbin, Heilongjiang, 150001, China. zhaofali320@126.com.

BMC Cardiovascular Disorders
|July 3, 2026
PubMed
Abstract

Insights

Evolocumab plus statin improved lipid profiles, renal artery hemodynamics, and showed potential renal benefits in patients with coronary artery disease and renal artery stenosis. Further prospective studies are needed for validation.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • Renal artery stenosis (RAS) is a primary cause of secondary hypertension.
  • Interventional therapies for RAS carry significant risks.
  • This study investigates novel lipid-lowering therapy in RAS patients with coronary artery disease (CAD).

Purpose of the Study:

  • To evaluate the impact of evolocumab plus statin therapy on lipid profiles.
  • To assess changes in renal artery hemodynamics and function.
  • To compare these effects against standard statin therapy alone.

Main Methods:

  • A retrospective cohort study of 57 CAD patients with RAS.
  • Patients received either evolocumab plus atorvastatin or atorvastatin alone.
  • Bilateral renal artery ultrasonography and laboratory tests were performed for follow-up.

Main Results:

  • Combination therapy significantly improved lipid profiles, creatinine levels, and renal artery parameters compared to statin alone (P < 0.05).
  • Lp(a) levels showed an increasing trend in the combination group.
  • Within-group analyses revealed improving trends, but only some lipid parameters achieved statistical significance.

Conclusions:

  • Evolocumab plus statin demonstrated potential benefits for lipids, renal hemodynamics, and renal function in this patient cohort.
  • Results suggest a possible renal benefit, warranting further investigation.
  • The study's exploratory nature, small sample size, and non-randomized design necessitate cautious interpretation and validation in prospective trials.
Keywords:
LipidPCSK9 inhibitorRenal artery stenosisRenal function

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...